Abstract
Clinically approved antiviral drugs are currently available for only 10 of the more than 220 viruses known to infect humans. The SARS-CoV-2 outbreak has exposed the critical need for compounds that can be rapidly mobilised for the treatment of re-emerging or emerging viral diseases, while vaccine development is underway. We review the current status of antiviral therapies focusing on RNA viruses, highlighting strategies for antiviral drug discovery and discuss the challenges, solutions and options to accelerate drug discovery efforts.
MeSH terms
-
Antiviral Agents / chemistry
-
Antiviral Agents / pharmacology*
-
Biological Products / chemistry
-
Biological Products / pharmacology
-
COVID-19 / prevention & control
-
COVID-19 / virology
-
COVID-19 Drug Treatment*
-
Coronavirus Protease Inhibitors / chemistry
-
Coronavirus Protease Inhibitors / pharmacology
-
Drug Discovery / methods*
-
Humans
-
Molecular Docking Simulation
-
Molecular Targeted Therapy / methods*
-
Nucleic Acid Synthesis Inhibitors / chemistry
-
Nucleic Acid Synthesis Inhibitors / pharmacology
-
Pandemics / prevention & control*
-
RNA, Viral / antagonists & inhibitors*
-
RNA, Viral / chemistry
-
RNA, Viral / genetics
-
RNA, Viral / metabolism
-
SARS-CoV-2 / chemistry
-
SARS-CoV-2 / drug effects
-
SARS-CoV-2 / enzymology
-
SARS-CoV-2 / genetics
-
Small Molecule Libraries / chemistry
-
Small Molecule Libraries / pharmacology
Substances
-
Antiviral Agents
-
Biological Products
-
Coronavirus Protease Inhibitors
-
Nucleic Acid Synthesis Inhibitors
-
RNA, Viral
-
Small Molecule Libraries